BrainStorm Cell Therapeutics Inc.

392 articles with BrainStorm Cell Therapeutics Inc.

• BrainStorm to Present at the Raymond James Human Health Innovations Conference

  6/11/2020

  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits, CEO and Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview on Thursday, June 18 at 9:00 am EST,

• BrainStorm to Participate in BIO Digital 2020

  6/3/2020

  BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced Dr. Ralph Kern, M.D, President and Chief Medical Officer will present a corporate overview during the BIO International Convention, which has transitioned to a new and virtual event and has been renamed BIO Digital.

• BrainStorm Announces that Pivotal Phase 3 Trial Remains on Track for Topline Data in Q4-2020

  6/2/2020

  The fully enrolled placebo-controlled Phase 3 trial is evaluating NurOwn® investigational treatment in ALS patients

• BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research

  5/27/2020

  Experience Developing, Seeking Regulatory Approval of and Commercializing Multi-Billion Dollar Neurology Therapies

• BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union

  5/7/2020

  BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced a lease agreement with the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel, to produce NurOwn® in three state-of-the-art cleanrooms.

• BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update

  5/7/2020

  BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the first quarter ended March 31, 2020 and recent corporate updates.

• BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology

  5/4/2020

  BrainStorm Cell Therapeutics Inc. announced that new data highlighting the immunomodulatory effects of NurOwn® on B and T regulatory function appeared in an online supplement to Neurology.

• BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 a.m. EDT

  4/29/2020

  BrainStorm-Cell Therapeutics Inc., a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced, that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2020, and provide a corporate update, at 8:30 a.m, Eastern Daylight Time, on Thursday, May 7, 2020.

• BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority

  4/3/2020

  BrainStorm Cell Therapeutics Inc. announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1.5 million by the Israel Innovation Authority.

• 

  BioSpace Movers & Shakers, April 3

  4/3/2020

  Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers.

• David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer

  4/1/2020

  International Pharmaceutical Veteran to Lead Global Business and Commercial Development

• BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors

  3/31/2020

  Prof. Frenkel, Chairman of the Group of Thirty (G-30) Board of Trustees, Former Chairman of JPMorgan Chase International and Former Governor of the Bank of Israel Joins the Board to Support the Company’s Global Expansion

• BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19

  3/16/2020

  Funding Secured and Senior Management Team Activated by CEO to Ensure Advancement of all Operational Activities and Completion of Corporate Clinical Milestones

• BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share

  3/6/2020

  BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has entered into a definitive agreement with Abbhi Investments, LLC, a healthcare-focused family office based in Miami, Florida, in connection with a privately negotiated sale of common stock and  a warrant to purchase common stock (collectively, the “securities”).

• 

  Clinical Catch-Up: February 24-28

  3/2/2020

  The month of February ended with a flurry of clinical trial announcements. Here’s a look.

• Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial

  2/27/2020

  BrainStorm Cell Therapeutics Inc. announced that Partners MS Center at Brigham and Women’s Hospital, a leading research and clinical care center, has contracted with BrainStorm as a clinical study site for the Company’s Phase 2 open-label, multicenter study of repeated intrathecal administration of NurOwn® in participants with progressive Multiple Sclerosis.

• BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019 Conference Call and Webcast @ 8:00 a.m. Eastern Time Today

  2/18/2020

  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for fiscal year ended December 31, 2019.

• BrainStorm’s Chief Operating Officer to Present at Noble Capital Markets’ Sixteenth Annual Investor Conference

  2/17/2020

  BrainStorm Cell Therapeutics Inc. announced that Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, will provide a clinical update on the Company’s ALS and MS trials and present insights on the future growth strategy of BrainStorm at the Noble Capital Markets’ Sixteenth Annual Investor Conference, taking place February 16-18, 2020 at the Hard Rock Hotel & Casino, Hollywood, Florida.

• BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS

  2/11/2020

  BrainStorm Cell Therapeutics, Inc. announced that the Company recently held a high level meeting with the U.S. Food and Drug Administration to discuss potential NurOwn® regulatory pathways for approval in ALS.

• BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update

  2/10/2020

  BrainStorm Cell Therapeutics, Inc. announced that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and full year ended December 31, 2019, and provide a corporate update, at 8:00 a.m., Eastern Time, on Tuesday, February 18, 2020.